Product Description
Alvocidib is a synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. It has a role as an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an antirheumatic drug and an apoptosis inducer. It is a dihydroxyflavone, a hydroxypiperidine, a member of monochlorobenzenes and a tertiary amino compound. It is a conjugate base of an alvocidib(1+). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Alvocidib)
Mechanisms of Action: CDK9 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Lymphocytic Chronic B-Cell Leukemia|Prolymphocytic Leukemia|Chronic Lymphoid Leukemia|Esophageal Cancer|Melanoma|Prolymphocytic B-Cell Leukemia|Multiple Myeloma|Breast Cancer|Ovarian Cancer|Peritoneal Cancer|Leukemia, Plasma Cell|Mycosis Fungoides|Diffuse Large B-Cell Lymphoma|Adult T-Cell Leukemia-Lymphoma|T-Cell Cutaneous Lymphoma|B-Cell Marginal Zone Lymphoma|Multiple Sclerosis|Waldenstrom Macroglobulinemia|Mantle-Cell Lymphoma|Lymphomatoid Granulomatosis|Lymphoma, Non-Hodgkin|Immunoblastic Lymphadenopathy|Large-Cell Anaplastic Lymphoma|Large-Cell Immunoblastic Lymphoma|Acute Myeloid Leukemia|Sezary Syndrome|Follicular Lymphoma|Acute Myelomonocytic Leukemia|Liver Cancer|Prostate Cancer|Endometrial Cancer|Acute Basophilic Leukemia|Acute Megakaryoblastic Leukemia|Myelodysplastic Syndrome|Hypereosinophilic Syndrome|Acute Monocytic Leukemia|Acute Erythroblastic Leukemia|Preleukemia|Kidney Cancer|Seminoma|Acute Lymphoid Leukemia|Thromboembolism|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Pancreatic Cancer|Lymphoma, B-Cell|Acute Eosinophilic Leukemia|Squamous Cell Carcinoma|Adenocarcinoma|Renal Cell Carcinoma|Head and Neck Cancer|Testicular Cancer|Germinoma|Gastrointestinal Cancer|Sarcoma
Phase 1: Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Lymphoma|Male Breast Cancer|Thrombocytopenia|Acute Erythroblastic Leukemia|Lymphoma, B-Cell|Acute Myeloid Leukemia|Mantle-Cell Lymphoma|Hairy Cell Leukemia|Follicular Lymphoma|Blast Crisis|Prostate Cancer|Prolymphocytic B-Cell Leukemia|Hypereosinophilic Syndrome|Anemia, Refractory|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Anemia, Refractory, with Excess of Blasts|Prolymphocytic Leukemia|Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Lymphoproliferative Disorders|B-Cell Marginal Zone Lymphoma|Acute Basophilic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Intestinal Cancer|Waldenstrom Macroglobulinemia|Acute Megakaryoblastic Leukemia|Acute Lymphoid Leukemia|Chronic Myelomonocytic Leukemia|Acute Eosinophilic Leukemia|Pancreatic Cancer|Leukemia|Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Multiple Myeloma|Adenocarcinoma|Oncology Solid Tumor Unspecified|Skin Cancer|Peripheral Neuroectodermal Tumors, Primitive|Embryonal Rhabdomyosarcoma|Kidney Diseases|Supratentorial Cancer|Primitive Neuroectodermal Tumors|Liver Cancer|Hypothalamic Cancer|Astrocytoma|Sarcoma|Optic Nerve Cancer|Medulloblastoma|Neuroblastoma|Wilms Tumor|Optic Nerve Glioma|Soft Tissue Cancer|Lymphoid Leukemia|Sarcoma, Ewing|Retinoblastoma|Ependymoma|Melanoma|Breast Cancer|Brain Stem Cancer|Kidney Cancer|Gastrointestinal Stromal Tumors|Osteosarcoma|Cerebellar Cancer|Esophageal Cancer|Non-Small-Cell Lung Cancer|Mesothelioma|Oncology Hematological Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2017-001178-41 | P2 |
Terminated |
Acute Myeloid Leukemia |
2021-10-10 |
|
| TPI-ALV-102 | P2 |
Terminated |
Myelodysplastic Syndrome|Preleukemia |
2021-08-16 |
|
| TPI-ALV-202 | P2 |
Terminated |
Acute Myeloid Leukemia |
2021-04-22 |
|
| M16-186 | P1 |
Completed |
Acute Myeloid Leukemia |
2021-01-25 |
41% |